J. David Hansen
President, CEO and Chairman
David Hansen serves as the President, Chief Executive Officer, and Chairman of the Board of Directors. Mr. Hansen is an experienced biopharmaceutical executive with more than 30 years of industry experience. He has held senior management roles in both private startup companies as well as small to mid-sized public companies. His senior level experience includes executive management, finance and accounting, corporate development, and sales and marketing. During his career, he has executed a wide variety of in and out licensing agreements, research and development collaborations, joint ventures, divestitures, and acquisitions. He has developed expertise in the therapeutic areas of immunology, oncology, and infectious disease. He gained executive management experience at several life sciences companies prior to co-founding the Company, making him particularly suited for his leadership role at MabVax. He was a corporate officer of Avanir Pharmaceuticals where he held the titles of Vice President of Commercial Development, Senior Vice President of Corporate Development, and President and Chief Operations Officer of the Avanir Subsidiary Xenerex Biosciences in which is was a founder. Prior to Avanir, he served in multiple roles at Dura Pharmaceuticals including National Sales Director, Director of Marketing, and Director of Business Development. He has additional management experience with Merck & Co. (Schering-Plough), Key Pharmaceuticals, and Bristol Myers Squibb.
Gregory P. Hanson, C.M.A., M.B.A.
Chief Financial Officer
Gregory P. Hanson, C.M.A., M.B.A., serves as the CFO of MabVax. Mr. Hanson has over 30 years' experience serving as the CFO, financial executive and board member of public and private life sciences and hi-tech companies. Since October 2016, he has served as a member of the board of directors of WCCT, Inc., a private pharmaceutical contract research organization. Previously, Mr. Hanson served on the Advisory Board of Menon International and Brinson Patrick Securities. His executive level experience includes CFO at Avanir Pharmaceuticals and Mast Therapeutics and investment banking at Brinson Patrick Securities. Mr. Hanson is Past-President and 11-year Member of the Board of Directors of San Diego Financial Executives International (FEI). Mr. Hanson was a founding and 6-year member of the Small Business Advisory Committee to the Financial Accounting Standards Board (FASB), and has spoken at various national conferences, industry organizations and panels on financing strategy and mergers and acquisitions, and twice spoken to the SEC's Committee on Improvements to Financial Reporting.
Mr. Hanson has passed the examination for Certified Public Accountants and is a Certified Management Accountant. He has an MBA with distinction from the University of Michigan, and a BS in Mechanical Engineering from Kansas State University. From 2008 to September 2016 Mr. Hanson maintained Series 7 & Series 63 securities licenses.
Philip O. Livingston, M.D.
Chief Science Officer
Philip O. Livingston, M.D., serves as a member of the Board of Directors and Chief Science Officer and, prior to the Merger, served as a member of the Board of Directors and Chief Science Officer of MabVax Therapeutics, Inc., from 2012. Dr. Livingston received his M.D. degree from Harvard Medical School, was Professor of Medicine in the Joan and Sanford Weill Medical College at Cornell University, and was also Attending Physician and Member in Memorial Sloan-Kettering Cancer Center (MSKCC), where he treated melanoma patients and ran the Cancer Vaccinology Laboratory research lab for over 30 years. His research focused on identification of suitable targets for immunotherapy of a variety of cancers, construction of polyvalent conjugate vaccines specifically designed to augment antibody responses against these targets, and identification of optimal immunological adjuvants to further augment the potency of these vaccines. He has more than 150 publications and four issued and three pending patents concerning cancer vaccines. Recently, he helped establish MabVax Therapeutics, Inc., and Adjuvance Technologies, Inc., another biotech company.
Paul W. Maffuid, Ph.D.
Executive VP of Research and Development
Paul W. Maffuid, Ph.D., serves as Executive Vice President of Research and Development. Dr. Maffuid joined the Company in July 2014 as Vice President of Pharmaceutical Operations. He has more than 30 years of pharmaceutical industry experience includeing global pharmaceutical organizations, developing biotechnology companies and contract development and manufacturing organizations. His senior level management experience includes leadership for product development, manufacturing and drug disposition. Prior to joining MabVax, he gained executive management experience AAIPharma Services , Biopharmalogics, , Irvine Pharmaceutical Services and Arena Pharmaceuticals. While at Arena Pharmaceuticals, he was a member of the executive management team, responsible for drug product and drug disposition research and development operations, and led the design and construction of a cGMP compliant pilot manufacturing facility. Dr. Maffuid's management experience also includes Amylin Pharmaceuticals, Magellan Laboratories and Glaxo Research Institute (currently GSK).
Paul F. Resnick, M.D., M.B.A.
Vice President and Chief Business Officer
Paul F. Resnick, M.D., M.B.A., serves as Vice President and Chief Business Officer. Dr. Resnick joined the Company in March 2016. January 2013 to March 2016, Dr. Resnick was Senior Vice President, Business Development for Juventas Therapeutics, where he was responsible for business and commercial strategy and working with executive management overseeing corporate clinical development and financial and business strategies. From February 2012 to December 2012, he was an advisor for several companies in the life sciences area. From January 2008 to January 2012, he was Vice President of Business Development for Intellikine, Inc., responsible for managing alliances and leading the business development strategy that resulted in securing the acquisition by Takeda Pharmaceuticals. He was Senior Director for Worldwide Business Development and for Strategic Alliances at Pfizer Inc., where he was responsible for networking with leaders from biotechnology companies, universities and research institutions to gain early insights into emerging technologies, and for leading technical and business diligence, negotiations and alliance management of science and technology initiatives for Pfizer's Biotechnology and Bio-innovation Center. Prior to Pfizer, Dr. Resnick held Director and Senior Director positions at Rinat Neuroscience (acquired by Pfizer), Intermune, Inc. and Roche Pharmaceuticals.
Dr. Resnick holds an M.D. from the Medical College of Wisconsin and an M.B.A. from the Wharton School of the University of Pennsylvania.
Wolfgang W. Scholz, Ph.D.
Vice President of Antibody Discovery
Wolfgang W. Scholz, Ph.D. serves as Vice President of Antibody Discovery and, prior to the Merger, in 2014, was a co-founder and the Vice President of Antibody Discovery of MabVax Therapeutics, Inc. Dr. Scholz has extensive drug discovery experience in multiple therapeutic categories and has collaborated with major pharmaceutical companies on several projects. He was Senior Director at Avanir Pharmaceuticals, where he led research and development efforts for eight years, and was a co-founder of Xenerex Biosciences, a subsidiary owned by Avanir Pharmaceuticals. Under his leadership, the antibody discovery group at Xenerex developed human monoclonal antibodies to multiple infectious disease targets using in vitro and SCID mouse technologies. One antibody (AVP-21D9) was successfully out-licensed and recently passed Phase 1 safety testing. Prior to Avanir, he held positions with increasing responsibilities at Tanabe Research Laboratories. Over his career his work has been funded by multiple grants from the National Institute for Allergy and Infectious Diseases. He is the Principal Investigator on multiple National Cancer Institute grants received by MabVax, totaling almost $5 million. Dr. Scholz is an inventor on three pending and three issued antibody patents, three issued small molecule patents, and author on 34 peer-reviewed publications.
Dr. Scholz earned his Ph.D. in Microbiology and Immunology from the University of Kiel, Germany in 1985 and completed his postdoctoral training at The Scripps Research Institute, La Jolla.